Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Insmed Incorporated has announced its phase 2b CEDAR trial evaluating brensocatib, a dipeptidyl peptidase 1 (DPP1) inhibitor, in adults with moderate to severe 

 failed to achieve both its primary and secondary efficacy endpoints.

In their April 2026 release, the failure of brensocatib to meet its efficacy endpoints in this new analysis and led the company to discontinue any further development of the therapy for this indication. Despite this, Insmed is slated to present full study results at a future scientific meeting.

"The CEDAR study was designed as a proof-of-concept study to determine whether brensocatib could provide benefit for patients with HS—a disease where the lack of established animal models makes clinical development particularly challenging," Martina Flammer, MD, MBA, Chief Medical Officer of Insmed, said in a statement.

The CEDAR analysis was designed as a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of brensocatib across a global cohort of 214 patients, all of whom were enrolled at 72 sites. Those involved were given an assigment, in a 1:1:1 ratio, to once-daily receive brensocatib either at a 10 mg or 40 mg dose or placebo. This treatment schedule took place over an initial 16-week treatment period.

Following this phase of CEDAR, investigators had subjects either continue their assigned brensocatib dose or, if originally assigned to placebo, re-randomized them to be given active treatment. CEDAR’s primary endpoint was the percent change from the point of baseline in participants’ total abscess and inflammatory nodule (AN) count by the 16-week mark. At that time point, reductions in AN count were observed across all groups.

However, the investigative team noted outcomes in the active treatment arms did not surpass those observed among patients treated with placebo. Those on brensocatib 10 mg and 40 mg experienced mean reductions of 45.5% and 40.3%, respectively. This was compared with a 57.1% reduction among those in the placebo arm of the study.

Despite the lack of demonstrated efficacy, the team highlighted brensocatib’s consistent safety profile with prior clinical research. The CEDAR investigators reported a lack of new safety concerns, including in the higher 40 mg dosing arm, which represents the highest dose evaluated by Insmed to date. Rates of treatment-emergent adverse events (TEAEs) were noted as comparable across study cohorts.

During the placebo-controlled period, TEAEs took place among 41 individuals in the 10 mg arm, 30 in the 40 mg arm, and 32 on placebo. Severe adverse events (AEs) were rare, with a single event reported in the 10 mg arm and none in the other arms. Serious AEs were identified by the investigators in 3, 1, and 1 individuals in the 10 mg, 40 mg, and placebo arms, respectively.

Brensocatib previously received approval from the US Food and Drug Administration for the treatment of adult and pediatric patients aged 12 years and older with non-cystic fibrosis bronchiectasis at doses of 10 mg and 25 mg.

 While it discontinued its HS program for this drug, the company’s release highlights the benefits of these findings.

"While we are disappointed in the results, we hope that insights gained from this study will contribute to the broader scientific understanding of HS,” Flammer said in a statement.

 “We are grateful to the patients and investigators who participated in this study."

Insmed Provides Clinical Update on Phase 2b CEDAR Study. Insmed. April 7, 2026. Accessed April 14, 2026. 

https://www.prnewswire.com/news-releases/insmed-provides-clinical-update-on-phase-2b-cedar-study-302736190.html

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease. News release. Insmed. August 12, 2025. Accessed April 14, 2026. 

https://investor.insmed.com/2025-08-12-FDA-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-for-Non-Cystic-Fibrosis-Bronchiectasis,-a-Serious,-Chronic-Lung-Disease

Articles

Insmed’s phase 2b CEDAR trial of brensocatib, an oral DPP1 inhibitor, in moderate-to-severe hidradenitis suppurativa missed both primary and secondary efficacy endpoints, prompting discontinuation of development in HS. In a 214-patient, randomized, double-blind, placebo-controlled design (10 mg, 40 mg, placebo), abscess and inflammatory nodule counts decreased across all arms at 16 weeks, but placebo numerically outperformed active treatment. Safety was consistent with prior experience, with comparable TEAEs and few severe/serious events.

This phase 2b study on brensocatib did not meet its primary or secondary efficacy endpoints, causing Insmed to discontinue their HS program.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued

Neurological and Psychiatric Manifestations in Wilson Disease

In this episode, 'Neurological and Psychiatric Manifestations in Wilson Disease,' the panelists explore the complex and often nonspecific neurological and psychiatric landscape of Wilson disease. Dr. Peter Hedera describes the condition as a "great imitator" because it frequently mimics more common movement disorders such as Parkinson's disease, dystonia, and essential tremor. This clinical overlap often leads to significant diagnostic delays, sometimes lasting two years or longer. The experts stress that a high index of suspicion is required for any patient under the age of 40 or 50 presenting with unexplained movement symptoms.

The discussion also delves into the psychiatric side of the disease, noting that approximately 10% of patients may present with psychosis. This can create a diagnostic trap where neuroleptic treatments for psychiatric symptoms cause extrapyramidal side effects that further mask the underlying Wilson disease. In pediatric populations, the panelists shift the focus to neuropsychiatric indicators, such as sudden changes in school performance, cognitive shifts, or hyperkinetic movements like chorea.

Finally, the panel addresses the overlap between hepatic and neurological symptoms. While adults frequently show signs of both, pediatric patients under age 10 rarely exhibit neurological symptoms. However, that frequency increases to roughly 30% in adolescents. The experts conclude that while the coexistence of elevated liver enzymes and movement disorders is a major red flag, clinicians must rely on thorough laboratory confirmation to navigate these overlapping clinical presentations and ensure the best patient outcomes through early diagnosis.

The next episode in this series, 'Understanding Pathophysiology and Copper Transport in Wilson Disease,' features the panelists advancing their conversation on Wilson disease and focusing on the genetic and cellular mechanisms of the condition. Dr. Peter Hedera explains how mutations in the ATP7B gene disrupt copper homeostasis, leading to toxic accumulation in the liver and brain.

Videos

Panelists discuss the often misdiagnosed neurological and psychiatric manifestations of Wilson disease, highlighting its overlap with common movement and mental health disorders, the need for high clinical suspicion, and the importance of early diagnosis through careful evaluation of overlapping symptoms.

Video Series

Hepatic Symptoms and Clinical Presentations of Wilson Disease

Welcome back to another HCPLive Peer Exchange series. In this episode titled, 'Hepatic Symptoms and Clinical Presentations of Wilson Disease,' the moderator Dr. Frederick Askari, and expert panelists, Dr. Peter Hedera and Dr. Rima Fawaz, discuss the clinical spectrum of hepatic symptoms associated with Wilson disease.

The panel emphasizes that the majority of patients, particularly in the pediatric population, are often asymptomatic at the time of initial discovery. These cases are frequently identified through routine laboratory work that reveals unexplained elevations in liver enzymes. While patients might occasionally exhibit mild hepatomegaly or splenomegaly during an episode of acute hepatitis, many remain feeling generally well despite underlying pathology.

The experts transition to discussing more advanced liver involvement, noting that while asymptomatic presentation is the norm, clinicians must remain vigilant for signs of cirrhosis and portal hypertension. The liver is described as a sneaky organ that can mask significant damage. In some instances, Wilson disease is uncovered during diagnostic workups for other conditions, such as obesity related liver issues or suspected autoimmune hepatitis.

Finally, the discussion addresses the most severe and rare presentations. Although infrequent in children, Wilson disease can manifest as acute liver failure or present with complications like ascites and variceal bleeding. Dr. Fawaz points out that a high index of clinical suspicion is required for these cases, especially when accompanied by Coombs-negative hemolytic anemia. The segment concludes by reinforcing the primary clinical goal: early diagnosis and intervention before patients progress to these life-threatening stages.

In the next episode, 'Neurological and Psychiatric Manifestations in Wilson Disease,' panelists will continue their discussion on Wilson disease and highlight the diagnostic challenges of neurological and psychiatric presentations. The experts explain why the disease is often misdiagnosed as Parkinsonism or essential tremor and emphasize the importance of identifying neuropsychiatric shifts in pediatric patients.

Panelists discuss the often subtle and asymptomatic hepatic presentations of Wilson disease, emphasizing the importance of early detection, awareness of advanced complications, and maintaining clinical suspicion to prevent progression to severe liver outcomes.

Delainey Wescott, PhD, is a postdoctoral scholar in the Translational Research Training in Sleep and Circadian Science T32 program at the University of Pittsburgh School of Medicine.

Short Sleep Tied to Next-Day Depression in Suicidal Youth, With Delainey Wescott, PhD

 among adolescents and young adults receiving intensive treatment for depression and suicidality, according to data presented at the 2026 Anxiety and Depression Association of American (ADAA) in Chicago from April 9 – 11. Findings from an intensive longitudinal study suggest that heightened emotional reactivity to negative interpersonal events may help explain the relationship.

“What's even more important is that for folks who have more moderate to severe depression, that sleep loss to depression relationship is amplified, and so folks with more severe depression may be more vulnerable to the effects of sleep loss on next day depression,” Delainey Wescott, PhD, of the University of Pittsburgh School of Medicine, said in an interview with 

The longitudinal study included 198 adolescents and young adults aged 13-23 years (82% white participants; 76% female) undergoing intensive outpatient treatment for depression and suicide risk. Participants wore actigraphy devices and completed daily diaries assessing sleep duration, depression symptoms, and emotional responses to interpersonal events over an average of 60 days. Clinician-rated depression severity was also collected weekly. Multilevel models examined day-to-day associations between sleep and next-day depressive symptoms, and mediation analyses evaluated affective reactivity as a potential mechanism.

Over the course of treatment, self-reported sleep duration increased modestly (

 <.001), while daily self-reported depression decreased (

 =.02). However, actigraphy-measured sleep duration did not significantly change (

 = .16). The study ultimately showed that sleeping less than usual based on self-report was associated with greater next-day depression (

 =.02), whereas actigraphy-based sleep duration was not significantly associated after covariate adjustment (

Baseline depression severity moderated the relationship between sleep and next-day depression. Greater clinician-rated depression amplified the impact of short sleep duration on next-day depressive symptoms for both diary-based (

 =.03) and actigraphy-based sleep estimates 

 =.01). These findings suggest that youth with more severe depression may be particularly sensitive to sleep disruption.

The analysis also identified a potential mechanism linking sleep loss to worsening mood. Sleeping less than usual predicted increased negative emotional reactivity to interpersonal events, such as conflicts, perceived rejection, or feelings of exclusion. This heightened reactivity, in turn, was associated with greater next-day depression. Mediation models confirmed that increased negative affectivity statistically mediated the relationship between short sleep and depressive symptoms (

The findings have implications for clinical care, particularly in intensive outpatient settings, where sleep may be under-addressed. Wescott suggested that integrating sleep-focused strategies into higher-acuity treatment programs could improve outcomes. Potential approaches include promoting regular sleep-wake schedules, increasing sleep duration, and incorporating elements of cognitive behavioral therapy for insomnia or transdiagnostic sleep and circadian interventions.

Future research will evaluate whether directly targeting sleep in intensive outpatient programs improves clinical outcomes. Ongoing work aims to integrate sleep-focused interventions into treatment curricula and assess effects on depression and suicidality in high-risk youth.

“What's really unique about this data set is we were able to not only look at high risk youth…engaged in intensive outpatient treatment, but we're also able to follow them for up to 3 months, and so we're able to track the progression of treatment over time, but really understand those day-to-day relationships of sleep, of negative affectivity, of depression severity, to disentangle what might be happening on a day-to-day basis that may be maintaining some depression symptomatology,” Wescott said. “The unique study design and the unique sample of this study really allowed us to ask some interesting questions, which I think have some important clinical implications of the importance of treating sleep in high risk youth.”

Wescott D. Sleeping Less Than Usual Is Associated with Greater Next Day Depression and Higher Reactivity to Negative Interpersonal Events Among Suicidal Adolescents. Poster presented at ADAA in Chicago from April 9 – 11, 2026.

Wescott discusses ADAA 2026 findings linking sleeping less than usual to next-day depression in high-risk youth, with interpersonal reactivity emerging as a potential mechanism.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Howard Trachtman, MD, is an adjunct clinical professor of pediatrics at the University of Michigan.

Credit: International Society of Glomerular Diseases

 marks a major milestone as the first therapeutic option to treat 

focal segmental glomerulosclerosis (FSGS)

The April 13, 2026 decision was supported by data from the 

trials, 2 of the largest head-to-head interventional studies in adult and pediatric patients with FSGS.

Sparsentan is a first-in-class dual endothelin and angiotensin II receptor antagonist that simultaneously targets endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors. By inhibiting AT1, it reduces angiotensin II–mediated vasoconstriction and intraglomerular pressure. Simultaneously, by blocking the ETA receptor, sparsentan reduces inflammation, vasoconstriction, and fibrosis, and may help limit podocyte injury.

Through dual pathway inhibition, sparsentan has been shown to reduce proteinuria beyond what is achievable with maximal renin–angiotensin system blockade alone, with clinical data suggesting potential long-term kidney protective effects, including slowing the progression of kidney function decline.

Howard Trachtman, MD, an adjunct clinical professor of pediatrics at the University of Michigan, who served as a study investigator of the phase 3 DUPLEX trial, spoke about the implications and importance of this latest approval in an interview with 

: Sparsentan was approved yesterday as the first FDA-approved therapy for FSGS—what does this approval mean for the field and for patient care?

 It’s really, it’s an important milestone. It’s the first drug. Historically, FSGS has been like a graveyard for drug development. It’s a difficult disease, its outcomes are bad, and there’s been really marginal understanding of the pathophysiology of the disease.

So it’s been—I mean, I’ve been at this for a very long time—and most sponsors are very, very reluctant to get into the space. Diabetic kidney disease just really dwarfed any activity with regard to the primary glomerular diseases.

So the fact that people are finally paying attention to the disease—it’s even though it’s uncommon, I hate the word rare, but it’s uncommon—the health burden is enormous.

So there were just no treatments, no documented therapies that people would rely upon, that they did at accurate dosing, they did the side effect profile, and they could confidently talk to patients and to their parents and caregivers and say, “Well, this is what I would expect to happen with this drug.”

It’s just really a fantastic accomplishment. The drug itself is interesting because it combines antagonism of two pathways. But in the work that I’m involved with, and people at Michigan, there may be people who have more pronounced activation of the endothelin pathway who may be really poised to respond even better than average.

But this is a renal protective therapy. It works in patients with FSGS to achieve an important biological effect, namely reduction in proteinuria.

And again, the last thing I think that’s so important is that the approval was based on an endpoint that really opens the door to engagement with pharmaceutical companies, so that they know they have a measure of efficacy that can be considered by regulators.

As we really accelerate the scientific understanding of the heterogeneity of FSGS, clearly more drugs are going to come to the clinic for testing. And this trial really sets a standard that it can be done.

: You mentioned the trial opens the door for FSGS and more drugs being developed—can you tell us a little bit more about the data that leads you to believe in this positive future for the field?

Trachtman: With regard to the drug per se, again, what it is is a combination of the portion of the molecule that inhibits the renin–angiotensin system via angiotensin II type 1 receptor blockade, coupled with blockade of endothelin. Endothelin in and of itself is key. It’s documented to be a part of the pathophysiology of the disease.

And the fact that we know that these two injury pathways interact with one another, blocked simultaneously with a drug that, based on the coupled experience of DUET and DUPLEX, has a reassuring safety profile, is really, really valuable.

What the data show is that it causes an incremental reduction in proteinuria over and above what can be achieved with renin–angiotensin system blockade.

Knowing what we know about the data about the role of SGLT2 inhibitors in the context of FSGS—it’s a little bit inconclusive—it adds to what should I say, the elements of that renal protective box that can be offered to patients to lower proteinuria.

I think we’re learning that the better you do as clinicians lowering proteinuria, the better outcomes are for patients.

So I think what we’re seeing overall, depending on the different way that the FDA analyzed the data, is about a 20 to 25% incremental reduction in proteinuria over current standard of care.

: As you’ve mentioned proteinuria reduction, can you talk a little bit more about the other clinical markers investigators have seen with sparsentan, particularly in the context of eGFR slope and long-term kidney outcomes?

 It’s a great question. In the context of DUPLEX, and the open-label extension from DUET, the data would suggest that achieving these reductions in proteinuria at 2 years are clinically meaningful long term.

What PARASOL taught us was that it was implausible to document clinically meaningful changes in renal function preservation in a 2-year trial.

So with the DUPLEX data, all of it—whether it was the number of patients that had 40% decline in eGFR, 30% decline in eGFR, or who started to reach the endpoint of kidney failure—all of these endpoints trended towards a benefit of sparsentan.

None of them are statistically significant because the numbers are too small, the follow-up is too short, and the disease variability is high.

And in this study, there was a modest slowing in eGFR decline over the 2-year period.

But I think that, hopefully, as a community, we can organize and make sure that data is collected post-marketing. The nephrology community—we can get better at this. PARASOL shows that we actually can work together collegially and productively.

We can continue to monitor the long-term efficacy of sparsentan, showing that the proteinuria reduction and the clinical benefit will manifest 3, 4 years down the road in terms of preservation of kidney function and delaying the time that patients need to start dialysis or receive a kidney transplant.

: Looking ahead, as you know, there are still plenty of unmet needs in FSGS management—what are the greatest unmet needs that remain, and what should be the next priorities to improve clinical care?

Trachtman: Again, a very good question. I think the most important thing is to enhance our understanding of the underlying mechanisms of glomerular and podocyte injury that lead to FSGS.

We know that it’s not a single disease entity, and it’s a reflection of injury to the podocyte based on genetic factors, immunological factors, metabolic factors, and different signaling pathways.

I think the thrust of the research effort should be to improve our understanding of these different pathways. Couple that with thoughtful, rational development of drugs that can target these pathways.

And then making sure that we target the right drug to the right patient with FSGS, knowing that they’re not all the same—they’re subtypes—and we need to refine our understanding, our ability to resolve those subtypes, and then therefore pair the patient with a subtype with the appropriate medication.

: What do you hope to come out of this approval for the nephrology community?

 I think the only other key thing is that this approval of sparsentan really represents an important accomplishment in the nephrology community, where you really did have alignment of all the critical forces.

Patients were advocating for this, doctors were doing the work, other clinical researchers were designing clinical trials that leveraged basic science.

And I think this needs to be really like a model, a paradigm for how the community has to work together—listen to the patient voice, define priorities in terms of treatments, and then husband industry resources and couple them with academic centers so progress can be made.

These are hard diseases to study, and cooperation and collaboration is going to be key to really move the ball forward consistently.

Hillenbrand A. FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis. HCPLive. Published April 11, 2026. Accessed April 14, 2026. 

https://www.hcplive.com/view/fda-approves-sparsentan-for-focal-segmental-glomerulosclerosis

Johnson V. DUPLEX: Sparsentan Outperforms Irbesartan in Reaching Key Proteinuria Threshold in FSGS. HCPLive. Published 2025. Accessed April 14, 2026. 

https://www.hcplive.com/view/duplex-sparsentan-outperforms-irbesartan-key-proteinuria-threshold-fsgs

Sparsentan received FDA approval as the first therapy specifically indicated for focal segmental glomerulosclerosis, supported by the DUET and DUPLEX head-to-head programs spanning adult and pediatric populations. As a dual ETA and AT1 receptor antagonist, it extends beyond conventional RAAS blockade to deliver incremental proteinuria lowering with a generally reassuring safety profile. While 2-year trials were underpowered to prove hard renal outcomes, trends favored benefit and eGFR decline modestly slowed. The approval establishes a regulatory endpoint and catalyzes renewed investment in FSGS subtype-driven therapeutics.

A DUPLEX study investigator explains the data behind sparsentan's approval by the FDA. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

FDA News

Why Sparsentan’s FDA Approval Marks a Turning Point in FSGS, With Howard Tratchman, MD

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

Podcasts

In this new episode of the Skin of Color Savvy podcast, Nambudiri speaks on-site at the AAD 2026 meeting in Denver about the clinical image collection.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Updates on the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

Stephan Weidinger, MD, PhD, professor and chair for Dermatology at the Christian-Albrechts-University and director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein.

This interview with Stephan Weidinger, MD, PhD, at AAD 2026 highlights new data on lebrikizumab 

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

ADlong: Phase 3b Findings on Lebrikizumab in Atopic Dermatitis, With Stephan Weidinger, MD, PhD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

FDA fully approves sparsentan for FSGS, offering the first oral non-immunosuppressive option that targets podocyte injury and cuts proteinuria.

FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis

Suyog Mokashi, MD, is the director of strategy at the Temple Heart and Vascular Institute and the director of aortic and endovascular surgery in the Division of Cardiovascular Surgery at Temple University.

Mokashi discusses 2 recent studies which he co-authored, investigating the socioeconomic impacts on health across America and the healthcare sector’s growth.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Strategic Alliance Partnership

Socioeconomic Pressures and Clinical Gains in Heart Disease, With Suyog Mokashi, MD

Jose Clemente, PhD, associate professor of Genetics and Genomics and Immunology at the Icahn School of Medicine at Mount Sinai

Early allergen introduction, microbiome research, and immune programming studies suggest food allergy prevention may begin during infancy.

Dynamic Video

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

 The Early-Life Window: Can Food Allergy Be Prevented Before It Begins?

Professor and Chair of the Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases and in the Peter O'Donnell Jr. School of Public Health at UT Southwestern Medical Center in Dallas

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.


Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Joints, Weight, and Mental Health: Ixekizumab + Tirzepatide for PsA, With Joseph Merola, MD

Sophia Schneider, MD, MS, is an internal medicine resident at Brigham and Women’s Hospital.

Schneider discusses her analysis of the FINEARTS-HF trial, noting the apparent efficacy of finerenone regardless of sleep apnea presence.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Obstructive Sleep Apnea

Sleep Apnea Associated With Worsening HF Outcomes, With Sophia Schneider, MD, MS

This Q&A interview from AAD 2026 covers a number of notable tips for clinicians in dermatology regarding topical therapies.

What's New in Topical Dermatology Drugs, With Brad Glick, DO, MPH

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Positive 12-week induction data from Part A of the phase 2 trial highlight the potential best-in-class safety and efficacy of SPY001, a novel anti-α4β7 therapy.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

SPY001, An Anti-α4β7, Shows Promise in Phase 2 SKYLINE Trial for Ulcerative Colitis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Although the approval does not permit entrance into the market, this decision marks an important step to more universally accessible GLP-1 RAs.

Breaking News

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Latest News

Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued

Neurological and Psychiatric Manifestations in Wilson Disease

Hepatic Symptoms and Clinical Presentations of Wilson Disease

Short Sleep Tied to Next-Day Depression in Suicidal Youth, With Delainey Wescott, PhD

Why Sparsentan’s FDA Approval Marks a Turning Point in FSGS, With Howard Tratchman, MD